The State of the Problem of Achieving Extremely Low LDL Levels

Title:The State of the Problem of Achieving Extremely Low LDL Levels

Volume: 27 Issue: 37

Author(s): Victoria Korneva*, Tatiana Kuznetsova and Ulrich Julius

Affiliation:

• Petrozavodsk State University, Faculty Therapy Department, 185000 Lenin Ave., 33, Petrozavodsk,Russian Federation

Keywords: Low-density lipoprotein CH (LDL-C), PCSK9 inhibitors, statins, diabetes mellitus, immune system, malignant neoplasms, brain function.

Abstract: Patients who have achieved very low low-density lipoprotein CH (LDL-C) levels in clinical trials have shown the lowest cardio-vascular risk. The current clinical guidelines set such a concentration for LDL-C as < 1.4 mmol/L. However, the question of minimum permissible target values of the lipids remains unresolved. A number of experimental and clinical studies showed some unfavorable consequences of low LDL-C levels At the same time, the modern arsenal of lipid lowering drugs allows reducing LDL-C levels to extremely low values. This review presents an analysis of literature about the safety of low lipid spectrum parameters.

Cite this article as:

Korneva Victoria *, Kuznetsova Tatiana and Julius Ulrich , The State of the Problem of Achieving Extremely Low LDL Levels, Current Pharmaceutical Design 2021; 27 (37) . https://dx.doi.org/10.2174/1381612827999210111182030